Paradigm Peptides

What happened

Paradigm Peptides ceased operations in December 2025 following a federal plea entered in U.S. district court. The formal charges concerned SARMs labeled products that contained testosterone — testosterone is a Schedule III controlled substance under 21 U.S.C. § 802(41), and selling it without a license to do so is the underlying federal offense.

The peptide catalog was not the formal subject of the action. The charging documents reference the SARMs-with-testosterone products specifically. But the operation closed in its entirety as part of the plea resolution: the vendor's website went offline, the peptide catalog along with the SARMs catalog stopped shipping, and the customer-service channels stopped responding.

What we read

For this postmortem we synthesized: the publicly-available DOJ press release accompanying the December 2025 plea; the federal court filings from the Eastern District of (court detail withheld pending full unsealing) referenced in contemporaneous trade reporting; r/Peptides community threads from the 90 days preceding the plea; and the Peptide Catalog post-shutdown coverage. This is a forensic public-data piece, not a first-hand audit.

The pattern, again

Paradigm Peptides is the second of three top-tier US peptide vendors to close in the 2025–2026 cycle, all under structurally similar circumstances. The pattern across all three:

The first two cases share the same structural feature: the formal cause of action was not the peptide catalog. It was the controlled-substance handling on a parallel SARMs product line. The peptide catalog ceased operating because the operation it sat inside ceased operating.

This matters for the buyer because it means the public quality data on the peptide catalog (COAs, shipping reliability, customer service) is not predictive of operational continuity. A vendor can be running a clean peptide catalog and still close because of unrelated catalog decisions. Reading the COA is necessary but not sufficient.

Pre-shutdown signals that were visible

The Paradigm Peptides case had a longer public-record runway than the Amino Asylum case. The investigation reportedly began in mid-2024 based on charging-document references to evidence-collection dates. The 18-month window between investigation start and plea is long enough that the buyer-side public signals were visible.

What was visible in 2024–2025:

• DOJ press releases in March 2025 announcing an expansion of the SARMs-with-testosterone investigation track (no vendors named in the announcement, but the policy direction was public)
• Trade-press reporting through summer 2025 referencing "additional federal actions expected" against research-chemical vendors
• Community speculation on r/Peptides through autumn 2025 noting Paradigm's catalog changes (some SKUs removed, others repriced) — often a sign of legal counsel guidance during a pending case

None of these signals were proof of imminent shutdown. Each was a risk indicator. A buyer who was tracking the FDA Warning Letters database and DOJ press releases over 2024–2025 would have had Paradigm on a risk list well before the December plea.

Where the catalog migrated

Following the December 2025 plea, Paradigm Peptides customers migrated similarly to the post-Amino-Asylum migration pattern, with some specific differences:

• Ascension Peptides absorbed a portion of the GLP-1 customer base (see our Ascension Peptides preview profile)
• Pure Rawz absorbed a portion of the catalog-breadth seekers (see our Pure Rawz preview profile)
• A portion of the customer base migrated to non-US-domestic vendors (Swiss Chems and similar) following the second top-tier US closure in six months

The pattern was not uniform. Paradigm's customer base was more catalog-breadth-driven than Amino Asylum's (which was more price-driven), and the migration tracked accordingly.

Lessons for the buyer

Watch for parallel-product-line risk. A vendor running a clean peptide catalog alongside a less-clean SARMs or research-chemical line carries risk that the peptide-catalog COAs do not capture. The two top-tier US shutdowns of 2025 both involved this pattern.

Public investigation signals run on long timelines. The Paradigm case had an 18-month investigation runway. The buyer who tracked DOJ press releases and FDA Warning Letters had time to migrate before the plea. The buyer who only tracked vendor-side signals (COAs, prices, shipping speeds) did not.

Migrations cluster by vendor positioning. Customers don't migrate randomly after a closure; they migrate to the closest catalog-and-pricing match. Knowing the positioning of vendors in the cycle helps predict where displaced demand goes — which is also where the next quality risk concentrates.

Related

• Three vendors closed in 12 months - covers the Paradigm closure alongside Amino Asylum and Peptide Sciences
• FDA peptide enforcement, 2024-2026
• How peptide vendors fail: a taxonomy

• FDA Warning Letters database↗ — FDA
• Peptide vendors shut down 2025-2026↗ — The Peptide Catalog
• FDA peptide enforcement, 2024-2026 — vialaudit
• Three vendors closed in 12 months — vialaudit